Evaxion Biotech A/S (EVAX) Competitors

Protara Therapeutics (NASDAQ:TARA) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.

Do insiders and institutionals have more ownership in TARA or EVAX?

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media favor TARA or EVAX?

In the previous week, Evaxion Biotech A/S had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for Evaxion Biotech A/S and 9 mentions for Protara Therapeutics. Evaxion Biotech A/S's average media sentiment score of 0.71 beat Protara Therapeutics' score of 0.34 indicating that Evaxion Biotech A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion Biotech A/S	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer TARA or EVAX?

Protara Therapeutics received 11 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 65.38% of users gave Protara Therapeutics an outperform vote while only 63.89% of users gave Evaxion Biotech A/S an outperform vote.

Company	Underperform	Outperform
Protara Therapeutics	Outperform Votes 34 65.38%	Underperform Votes 18 34.62%
Evaxion Biotech A/S	Outperform Votes 23 63.89%	Underperform Votes 13 36.11%

Is TARA or EVAX more profitable?

Protara Therapeutics has a net margin of 0.00% compared to Evaxion Biotech A/S's net margin of -347.83%. Evaxion Biotech A/S's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-57.66%	-50.71%
Evaxion Biotech A/S	-347.83%	N/A	-79.40%

Which has higher earnings and valuation, TARA or EVAX?

Evaxion Biotech A/S has higher revenue and earnings than Protara Therapeutics. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$40.42M	-$2.82	-0.91
Evaxion Biotech A/S	$70K	144.28	-$22.12M	-$0.29	-6.24

Do analysts recommend TARA or EVAX?

Protara Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 830.23%. Evaxion Biotech A/S has a consensus price target of $11.00, indicating a potential upside of 507.73%. Given Protara Therapeutics' higher possible upside, research analysts plainly believe Protara Therapeutics is more favorable than Evaxion Biotech A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evaxion Biotech A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, TARA or EVAX?

Protara Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Summary

Protara Therapeutics beats Evaxion Biotech A/S on 8 of the 15 factors compared between the two stocks.